Hairy cell leukemia – diagnostics, treatment and monoclonal antibodies
Authors:
R. Greksák
Authors‘ workplace:
Národný onkologický ústav, Oddelenie klinickej onkológie, Bratislava
Published in:
Transfuze Hematol. dnes,16, 2010, No. 3, p. 158-165.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
A significant progress was achieved in diagnostics and treatment of hairy cell leukemia (HCL) over in the past 25 years. It was accompanied by the achievement of important responses after treatment with interferon-α (IFN-α) but mainly with purine analogues 2-deoxycoformycine and 2-chlorodeoxyadenosine (2-DCF, 2-CdA). In most patients long-term survival without symptoms of disease may be achieved. There is a proportion of patients whose leukemia is resistant to standard treatment or relapse after a short period of remission. Search for new therapeutic modalities, that can ensure the elimination of hairy cells, is important for relapsed and refractory leukemia. Monoclonal antibodies (rituximab), and recombinant imunotoxins consisting of one chain of immunoglobulin bound with pseudomonas toxin (BL22, LMB-2), are in the centre of interest. The mechanism of action of these drugs is different from chemotherapy and IFN-α, and brings efficiency in pretreated patients. Presently, HCL is one of the oncological diseases with a relatively good prognosis with a majority of patients achieving long-term survival in remission thanks to available effective therapeutic options.
Key words:
immunotoxins, interferon-α, monoclonal antibodies, purine analogs, hairy cell leukemia
Sources
1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958; 13: 609-630.
2. Schrek R, Donnelly WJ. Hairy cells in blood in lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. Blood 1966; 27: 199-211.
3. Oleske D, Golomb HM, Farber MD, Levy PS. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol 1985; 121: 675-683.
4. Stewart DJ, Keating MJ. Radiation exposure as a possible etiologic factor in hairy cell leukemia. Cancer 1980; 46: 1577-1580.
5. Foroni L, Catovsky D, Luzzato L. Immunoglobulin gene rearrangements in hairy cell leukemia and other chronic B-cell lymphoproliferative disorders. Leukemia 1987; 4: 389-392.
6. Katayama I. Bone marrow in hairy cell leukemia. Hematol Oncol Clin North Am 1988; 2: 585-602.
7. Levine PH, Katayama I. The platelet in leukemic reticuloendotheliosis. Functional and morphological evidence of a qualitative disorder. Cancer 1975; 36: 1353-1358.
8. Rosove MH, Naeim F, Harwig S, Sighelboim J. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy. Blood 1980; 55: 903-906.
9. Depuy E, Sigaux F, Brychaert MC, et al. Platelet acquired defect in PDGF and ß-thromboglobulin content in hairy cell leukemia: improvement after interferon therapy. Brit J Haematol 1987; 65: 107-110.
10. Podzimek K, Kerekeš Z, Chrobák L, et al. The value of bone marrow biopsy in the prognosis of hairy cell leukemia. Neoplasma 1994; 41: 325-330.
11. Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1982; 61: 349-352.
12. Li CY, Yam LT, Lam KW. Studies of acid phosphatase isoenzymes in human leukocytes: demonstration of isoenzyme specificity. J Histochem Cytochem 1970; 18: 901-910.
13. Micklem KJ, Dong Y, Willis A, et al. HML-1 antigen on mucosa-associated T cells, activated cells, and hairy leukemic cells is a new integrin containing the ß7 subunit. Am J Pathol 1991; 139: 1297-1301.
14. Steis RG, Marcon L, Clark J, et al. Serum solubile IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988; 71: 1304-1309.
15. Chrobák L, Podzimek K, Plišková L, et al. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia. Neoplasma 1996; 43: 321-325.
16. Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108: 378-382.
17. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leukemia Lymph 1994; 14: 57-61.
18. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004; 199: 59-68.
19. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004; 363: 1869-1871.
20. Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D. p53 deletion and trisomy 12 in hairy cell leukemia. Leukemia Res 1999; 23: 1041-1045.
21. Palomera L, Domingo JM, Sola C, et al. Cladribine therapy in hairy cell leukemia variant. A report of three cases. Haematologica 2002; 87: 107-108.
22. Polliack A. Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 2002; 6: 366-388.
23. Žák P. Vlasatobuněčná leukemie (In: Leukemie, 1. vyd.), Avicenum, Grada Publishing, Praha 2002; 336-339, ISBN 80-7169-991-8.
24. Golde DW. Therapy of hairy-cell leukemia. N Engl J Med 1982; 307: 495-496.
25. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984; 310: 15-18.
26. Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon-alpha-2a. Blood 1990; 75: 839-845.
27. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Leukemia Lymph 1994; 13: 307-316.
28. Damasio EE, Clavio M, Masoudi B, et al. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. Eur J Haematol 2000; 64: 47-52.
29. Zinzani PL, Lauria F, Salvucci M, et al. Hairy cell leukemia and α-interferon treatment: long term responders. Haematologica 1997; 82: 152-155.
30. Spiers ASD, Parekh SJ, Bishop SJ. Hairy cell leukemia: Induction of complete remission with pentostatin (2-deoxycoformycin). J Clin Oncol 1984; 2: 1336-1342.
31. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long-term follow-up of patients with hairy cell leukemia after treatment with pentostatin or cladribine. Brit J Haematol 1999; 106: 515-519.
32. Ribeiro P, Bouaffia F, Peaud PY, et al. Long-term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999; 85: 65-71.
33. Golomb HM, Dodge R, Mick R, et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia 1994; 8: 2037-2040.
34. Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2-deoxycoformycin. Ann Intern Med 1993; 119: 278-283.
35. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117-1121.
36. Saven A, Burian C, Koziol JA, Piro LD. Long term follow up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.
37. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): Long-term follow-up of the Northwestern University experience. Blood 2005; 106: 241-246.
38. Robak T, Blasinska-Morawiec M, Blonski J, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999; 62: 49-56.
39. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989-995.
40. Žák P. Vlasatobuněčná leukemie a přínos 2-chlorodeoxyadenosinu v léčbě. Nucleus, Hradec Králové 2006, 44-45, ISBN 80-87009-03-7.
41. Žák P, Chrobák L, Dědic K. Minimal residual disease, its detection and significance in hairy cell leukemia. Acta Medica (Hradec Králové) 1999; 42: 85-88.
42. Bengio R, Narbait MI, Sarmiento MA, Palacios MF, Scolnik MP. Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia. Haematologica 2000; 85: 1227-1229.
43. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5: 1665-1670.
44. Ravandi F, Jorgensen JL, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107: 4658-4662.
45. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51: 364-369.
46. Hagberg, G. Chimeric monoclonal anti-CD20 antibody (rituximab) – an effective treatment for a patient with relapsing hairy cell leukemia. Med Oncol 1999; 16: 221-222.
47. Hoffman M, Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab in a patient refractory to cladribine. Brit J Haematol 2000; 109: 900-901.
48. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Brit J Haematol 2001; 115: 609-611.
49. Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906-3911.
50. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004; 73: 412-417.
51. Zenhäusern R, Simcock M, et al. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematol 2008; 93: 1426-1428.
52. Fietz T, Rieger K, Schmittel A, Thiel E, Knauf W. Alemtuzumab (Campath-1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J 2004; 5: 451-452.
53. Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol 2003; 74: 227-230.
54. Schulz H, Winkler U, Staak JO, et al. The monoclonal antibodies Campath-1H and Rituximab in the therapy of chronic lymphocytic leukemia. Onkologie 2000; 23: 526-532.
55. Kreitman RJ, Margulies I, Stetler-Stevenson M, et al. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 2000; 6: 1476-1487.
56. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23: 6719-6729.
57. Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin in Immunol 1999; 11: 570-578.
58. Matutes E, Wotherspoon A, Brito-Babapulle V, et al. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001; 15: 184-186.
59. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant imunotoxin BL22 in chemotherapy-resistant hairy cell leukemia. N Engl J Med 2001; 345: 241-247.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2010 Issue 3
Most read in this issue
- Hairy cell leukemia – diagnostics, treatment and monoclonal antibodies
- Follicullar lymphoma and the significance of its tumour microenvironment
- Cytomegalovirus – specific cellular imunity: profile of immune function assesment provides clinically relevant answer
- Immunophenotypic characterization of acute leukemias of ambiguous lineage- new diagnostic entity of the revised WHO classification 2008